Bevacizumab + capecitabine not cost effective in mCRC

  • PDF / 113,980 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 48 Downloads / 209 Views

DOWNLOAD

REPORT

1173-5503/13/0692-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved

PharmacoEconomics & Outcomes News 30 Nov 2013 No. 692

1

Data Loading...

Recommend Documents
Bevacizumab preferred option in mCRC

196 73 111KB

Capecitabine + irinotecan cost effective for colorectal cancer in China

154 88 163KB

Targeted immune modulators not cost effective in ulcerative colitis

146 89 163KB

Ivacaftor not cost effective in cystic fibrosis with G551D mutation

163 21 182KB

Patient-initiated DMARD self-monitoring service not cost effective

190 97 167KB

Guideline-based stepped care not cost effective for depression

171 104 184KB

Vaccinating boys along with girls against HPV not cost effective

141 15 139KB

Cost-Effective

168 109 57MB

Atorvastatin cost effective in T2DM

163 57 182KB

Atomoxetine cost-effective in ADHD

158 88 139KB

Tucatinib not cost effective in metastatic breast cancer in China and US

104 8 163KB

Highly Cost-Effective Intervention

195 83 57MB